Alteogen Enters Into A License Agreement With Biogen For Development And Commercialization Of Hybrozyme™-Based Subcutaneous Biologics

Reuters

Yesterday

Alteogen Inc <196170.KQ>::
*ALTEOGEN ENTERS INTO A LICENSE AGREEMENT WITH BIOGEN FOR DEVELOPMENT AND COMMERCIALIZATION OF HYBROZYME™-BASED SUBCUTANEOUS BIOLOGICS
*ALTEOGEN INC - TO RECEIVE $20 MILLION UPFRONT AND $10 MILLION UPON SECOND PRODUCT DEVELOPMENT
*ALTEOGEN INC - ELIGIBLE FOR UP TO $549 MILLION IN MILESTONE PAYMENTS FOR TWO PRODUCTS
*ALTEOGEN INC - FOLLOWING COMMERCIALIZATION, CO ENTITLED TO RECEIVE ROYALTIES BASED ON NET SALES
*ALTEOGEN INC - BIOGEN HOLDS OPTION TO DEVELOP THIRD PRODUCT UNDER AGREEMENT

((Reuters Investor Briefs; email: reutersinvestor.briefs@thomsonreuters.com))
Source Date/Time = 25-MAR-202612:00:01.867 GMT

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2622076803"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2622076803\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2622076803?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-25 20:44","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2622076803","market":"us","top_or_hot":-1,"title":"Alteogen Enters Into A License Agreement With Biogen For Development And Commercialization Of Hybrozyme™-Based Subcutaneous Biologics","media":"Reuters","content":"<html><body>Alteogen Inc &lt;196170.KQ&gt;::<br/>*ALTEOGEN ENTERS INTO A LICENSE AGREEMENT WITH BIOGEN FOR DEVELOPMENT AND COMMERCIALIZATION OF HYBROZYME™-BASED SUBCUTANEOUS BIOLOGICS<br/>*ALTEOGEN INC - TO RECEIVE $20 MILLION UPFRONT AND $10 MILLION UPON SECOND PRODUCT DEVELOPMENT<br/>*ALTEOGEN INC - ELIGIBLE FOR UP TO $549 MILLION IN MILESTONE PAYMENTS FOR TWO PRODUCTS<br/>*ALTEOGEN INC - FOLLOWING COMMERCIALIZATION, CO ENTITLED TO RECEIVE ROYALTIES BASED ON NET SALES<br/>*ALTEOGEN INC - BIOGEN HOLDS OPTION TO DEVELOP THIRD PRODUCT UNDER AGREEMENT<br/><br/>  ((Reuters Investor Briefs; email: reutersinvestor.briefs@thomsonreuters.com))<br/>  Source Date/Time = 25-MAR-202612:00:01.867 GMT</body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Alteogen Enters Into A License Agreement With Biogen For Development And Commercialization Of Hybrozyme™-Based Subcutaneous Biologics</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAlteogen Enters Into A License Agreement With Biogen For Development And Commercialization Of Hybrozyme™-Based Subcutaneous Biologics\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-03-25 20:44</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body>Alteogen Inc &lt;196170.KQ&gt;::<br/>*ALTEOGEN ENTERS INTO A LICENSE AGREEMENT WITH BIOGEN FOR DEVELOPMENT AND COMMERCIALIZATION OF HYBROZYME™-BASED SUBCUTANEOUS BIOLOGICS<br/>*ALTEOGEN INC - TO RECEIVE $20 MILLION UPFRONT AND $10 MILLION UPON SECOND PRODUCT DEVELOPMENT<br/>*ALTEOGEN INC - ELIGIBLE FOR UP TO $549 MILLION IN MILESTONE PAYMENTS FOR TWO PRODUCTS<br/>*ALTEOGEN INC - FOLLOWING COMMERCIALIZATION, CO ENTITLED TO RECEIVE ROYALTIES BASED ON NET SALES<br/>*ALTEOGEN INC - BIOGEN HOLDS OPTION TO DEVELOP THIRD PRODUCT UNDER AGREEMENT<br/><br/>  ((Reuters Investor Briefs; email: reutersinvestor.briefs@thomsonreuters.com))<br/>  Source Date/Time = 25-MAR-202612:00:01.867 GMT</body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IE00B19Z9Z06.USD","symbol_name":"Legg Mason ClearBridge - US Aggressive Growth A Acc USD","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260325:nRSD7Sz6hK:1","article_id":"2622076803","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2622076803","pubTimestamp":1774442692,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Alteogen Inc <196170.KQ>::*ALTEOGEN ENTERS INTO A LICENSE AGREEMENT WITH BIOGEN FOR DEVELOPMENT AND COMMERCIALIZATION OF HYBROZYME-BASED SUBCUTANEOUS BIOLOGICS*ALTEOGEN INC - TO RECEIVE $20 MILLION UP","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IE00B19Z9Z06.USD":"Legg Mason ClearBridge - US Aggressive Growth A Acc USD","BK4585":"ETF&股票定投概念","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","IE00B19Z9P08.USD":"LEGG MASON CLEARBRIDGE US AGGRESSIVE GROWTH \"A\" (USD) INC","BK4139":"生物科技","IE00B894F039.SGD":"Legg Mason ClearBridge - US Aggressive Growth A Acc SGD-H","LU0234570918.USD":"高盛全球核心股票组合Acc Close","BIIB":"渤健公司","BK4532":"文艺复兴科技持仓","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","BK4533":"AQR资本管理(全球第二大对冲基金)","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","BK4588":"碎股"},"translate_title":"Alteogen与Biogen就Hybrozyme的开发和商业化达成许可协议™基于皮下生物制剂","themeId":"ab6e84fb0542480d9cf75cb6a9fe5601","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BIIB":0.9},"content_text":"Alteogen Inc <196170.KQ>::*ALTEOGEN ENTERS INTO A LICENSE AGREEMENT WITH BIOGEN FOR DEVELOPMENT AND COMMERCIALIZATION OF HYBROZYME™-BASED SUBCUTANEOUS BIOLOGICS*ALTEOGEN INC - TO RECEIVE $20 MILLION UPFRONT AND $10 MILLION UPON SECOND PRODUCT DEVELOPMENT*ALTEOGEN INC - ELIGIBLE FOR UP TO $549 MILLION IN MILESTONE PAYMENTS FOR TWO PRODUCTS*ALTEOGEN INC - FOLLOWING COMMERCIALIZATION, CO ENTITLED TO RECEIVE ROYALTIES BASED ON NET SALES*ALTEOGEN INC - BIOGEN HOLDS OPTION TO DEVELOP THIRD PRODUCT UNDER AGREEMENT  ((Reuters Investor Briefs; email: reutersinvestor.briefs@thomsonreuters.com))  Source Date/Time = 25-MAR-202612:00:01.867 GMT","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":true,"code":"91000000","status":"200"}}}